Ocrevus, Gilenya May Limit Efficacy of COVID-19 Vaccines: UK Study

Ocrevus, Gilenya May Limit Efficacy of COVID-19 Vaccines: UK Study

315086

Ocrevus, Gilenya May Limit Efficacy of COVID-19 Vaccines: UK Study

COVID-19 infection rates after widespread vaccination were significantly higher among multiple sclerosis (MS) patients on Ocrevus (ocrelizumab) or Gilenya (fingolimod) than in the general population, but not among MS patients given other immunosuppressive disease-modifying therapies (DMTs), a data study in England reports. While information on patients’ vaccination status and timing in relation to DMTs was not available, these preliminary findings add to previous studies suggesting that Gilenya and B-cell-depleting therapies like Ocrevus may limit the…

You must be logged in to read/download the full post.